MedTech is where Switzerland’s deep heritage in precision engineering, microtechnology, and life sciences converges to solve critical healthcare challenges. This vertical is focused on tangible medical devices for surgery, patient monitoring, advanced diagnostics, and clinical support, integrating disciplines like robotics and AI to improve patient outcomes.

For this reason, “MedTech is Switzerland’s natural playground”. The ecosystem’s single greatest advantage is its “tight loop between engineers, clinicians, and regulators”, which allows startups to de-risk innovation and iterate solutions at a speed rarely seen elsewhere. With over 150 VC-backed startups and $1.4B in funding since 2019, the sector successfully integrates multiple disciplines to build value-based business models that are ready for global markets.

This page provides a detailed look at this powerhouse sector. Explore the key statistics, discover the “companies to watch” in fields from telerobotics to AI-powered diagnostics, and learn how Swiss MedTech teams are building the future of healthcare.


Notable Companies in MedTech

Key Stats*

VC-Backed startups


VC funding since 2019


Combined Enterprise Value


Tob Hubs in Zurich, Lausanne (EPFL) and Geneva.

* All data is taken from the Swiss Deep Tech Report 2025.


Companies to watch

Cell line technology for gene therapy.

Immune system rejuvenation.

Modular AI solutions accelerating drug discovery.

AI fingerprinting technology for molecular identification.

Genomic data.

Protein engineering.

Platform for cell and gene therapy manufacturing at scale.

RNA sequencing at scale.

The AI-first lab for protein design.

«The Swiss ecosystem gives Medtech teams the freedom to build, test, and scale ideas quickly. We see a tight loop between engineers, clinicians and regulators that lets us de-risk innovation fast. Once we prove a product here, we turn to the US for the deep capital, market scale and strategic partnerships that drive full commercial rollout and the path to public listing. By keeping robotics simple, surgeon-controlled, and cost-aligned, we can make advanced care a routine option for every hospital.»

Michael Friedrich

COO

Distalmotion

«Medtech is Switzerland’s natural playground. The depth of life science, shaped by Roche, Novartis, and a network of top universities, meets precision engineering, robotics, and increasingly Al. Integrating these dissimilar disciplines successfully is the key to innovation. Novel solutions allow to diagnose more accurately, treat more effectively, and build value based business models. It is at these crossroads of science and engineering where Zühlke Ventures keeps placing its bets.»

Patrick Griss

CEO Ventures & Partner

Zühlke


Who’s Who in MedTech


Most Active Swiss VCs in MedTech

MedTech
News

FAQ on MedTech

1. Why is MedTech considered Switzerland’s “natural playground”?

The sector perfectly combines the country’s historic strengths: deep life science expertise, precision engineering, robotics, and, increasingly, AI.

2. What is the total VC funding for MedTech in Switzerland?

The Swiss MedTech sector has raised $1.4 billion between 2019 and 2024, with funding growing 410% in that period. 2024 was its most active funding year on record.

3. How does the Swiss ecosystem benefit MedTech startups?

The “tight loop between engineers, clinicians, and regulators” allows startups to “de-risk innovation fast”. This rapid, collaborative iteration is a key advantage for building complex medical devices.

4. Which are the leading Swiss MedTech companies in surgical robotics?

The sector is anchored by major scale-ups like Distalmotion, which is commercializing its surgical robot, and rising stars like nanoflex (telerobotics) and LEM surgical.